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Introduction
Multiple, randomized controlled trials have provided solid evidence for the effi-
cacy and safety of tyrosine kinase inhibitors (TKI) as treatment for chronic myeloid
leukemia (CML), but analyses from observational studies, gathered in patients who
did not participate in clinical trials (the 'real-world') are scarce. Clinical trials use
tight inclusion criteria, strict rules for monitoring and treatment algorithms and
may, therefore, not fully reflect results in the general treatment population.1-3
Moreover, randomized controlled trials mainly focus on the outcome of the core
study treatment, while some patients will not be able to continue their initial study
treatment and are subsequently switched to an alternative treatment outside the
trial.4,5
To study treatment choices and patients’ outcome across different treatment
lines, real-world  data contain important information for clinical practice. Incidence
and survival have been the main focuses of the published reports of nationwide
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ABSTRACT
population-based registries. The large European popula-
tion-based EUTOS registry was the first to provide insight
into real-world first- and second-line treatment patterns in
relation to cytogenetic and molecular response.6 However,
this report did not cover deep molecular responses or the
proportion of patients meeting the criteria to attempt ces-
sation of TKI treatment. Discontinuing TKI therapy is a
novel opportunity in CML for patients with a durable
deep molecular remission, of whom approximately half
may successfully stop their TKI treatment while retaining
a 'treatment-free remission'.7,8
In the current article, we report findings from a nation-
wide population-based CML registry in the Netherlands
capturing data from newly diagnosed CML patients in the
majority of hospitals in our country. Detailed information
was collected on the patients’ characteristics and their
treatment, both at baseline and during follow-up.
Importantly, all TKI are available in the Netherlands and
the Dutch health care system includes mandatory health
care insurance which covers all CML care making it acces-
sible to all patients. 
The aim of the current study was to provide a detailed
overview of all aspects of CML care including responses to
first and subsequent treatment lines with a specific focus
on the impact of first-line treatment with imatinib com-
pared to that of the second-generation TKI, dasatinib and
nilotinib. We also sought to evaluate what proportion of
patients become eligible to attempt to stop their TKI treat-
ment. 
Methods
Data sources 
Data from two complementary Dutch population-based reg-
istries on CML patients (PHAROS-CML and Hemobase) were
combined to cover the nationwide population of adult (≥18 years)
CML patients diagnosed between January 2008 and April 2013 in
all 12 Dutch provinces. PHAROS-CML is an extension of the Dutch
Cancer Registry and consists of real-world data collected by trained
data managers from medical records of patients newly diagnosed
with CML between January 2008 and April 2013, covering the
Dutch population in 11 out of 12 provinces.9 Approval for this com-
prehensive data collection was obtained by the individual hospital
boards. The PHAROS-CML registry is a joint initiative of the
Dutch-Belgian Hemato-Oncology Group (HOVON), the Institute
of Medical Technology Assessment at the Erasmus University
Rotterdam and the Netherlands Comprehensive Cancer
Organization. Hemobase is a multidisciplinary web-based electron-
ic patients’ record in the north-eastern part of the Netherlands cov-
ering the one province that was not included in the PHAROS-CML
registry, which is the province of Friesland. The data in Hemobase
were registered by physicians and laboratory employees10 and
extracted from Hemobase to be combined with the PHAROS-CML
registry by the first author (IG) who verified each record to ensure
comparability. Together, data on all new CML patients in 75 of
approximately 90 hospitals in the Netherlands were available.
Additional molecular data were retrieved from all 15 Dutch molec-
ular laboratories performing BCR-ABL1 diagnostic testing. Data on
vital status and causes of death were obtained from the
Netherlands Cancer Registry with a follow-up until the 1st February,
2016. The Medical Ethics Committee of the Erasmus Medical
Center in Rotterdam authorized this study and the exemption from
informed consent. The study was conducted in accordance with
the Declaration of Helsinki.
Definitions and end-points
Disease phase according to the European LeukemiaNet crite-
ria,11 Sokal risk score,12 EUTOS long term survival (ELTS) score13
and Charlson Comorbidity index14 were calculated as described
in the original publications. Complete cytogenetic response was
defined as the absence of Philadelphia chromosome-positive
metaphases examined by chromosome banding. BCR-ABL1 lev-
els of ≤ 0.1%, ≤0.01% and ≤0.0032% on the international scale
or ≥3 log, ≥4 log and ≥4.5 log reduction of BCR-ABL1 mRNA
transcripts from baseline (in molecular laboratories not able to
report on the international scale at the time) were defined as the
molecular response end-points major molecular response
(MMR), MR4.0 and MR,4.5 respectively. Undetectable BCR-ABL1
levels were classified as a MMR when control gene numbers
were not available to determine the sensitivity of the test. 
In the case of a switch in TKI therapy, the clinical chart was
reviewed for the reason why the treating physician had changed
the therapy (‘treatment failure’ or ‘TKI intolerance’). As a proxy
for effective and tolerable first-line treatment 'effective first-line
treatment' was reached when patients continued their first-line
TKI for at least 1 year after achieving MMR. For the determina-
tion of eligibility to stop TKI, the inclusion criteria for the
EURO-SKI trial (ClinicalTrials.gov Identifier: NCT01596114)
were applied. In short, this required TKI treatment for a mini-
mum of 3 years, MR4.0 for at least 1 year and no history of TKI
switch for a less than optimal treatment response. Disease pro-
gression was defined according to European LeukemiaNet crite-
ria.11 Death due to CML was defined as death preceded by dis-
ease progression. 
Data analysis
Descriptive statistics were used to compare baseline character-
istics between treatment groups. Patients treated upfront with
nilotinib and dasatinib were clustered in the second-generation
TKI group for comparison with imatinib-treated patients. Overall
survival was analyzed using the Kaplan-Meier method with log-
rank test. All other time-dependent analyses were performed
using the cumulative incidence competing risks method. Death
and progression were always considered a competing risk.
Additional competing risks per specific analysis are shown in
Online Supplementary Table S1. A P-value of less than 0.05 was con-
sidered statistically significant. All analyses were performed using
SPSS version 24 and R-software15 version 3.2.4.
Results
Population description 
The registries covered 457 patients newly diagnosed
with CML between January 2008 and April 2013 in the
Netherlands. The 75 out of 90 Dutch hospitals participat-
ing in the registry differed in size and type (academic ver-
sus non-academic) and therefore provided an accurate rep-
resentation of the performance of CML treatment in the
Netherlands. At diagnosis, 434 patients were in chronic
phase ( 95%), eight patients (2%) in accelerated phase and
seven patients (1%) in blast crisis. Disease phase was
unknown for eight patients (2%). For all 457 patients, fol-
low-up information on survival status and death due to
CML was available until February 1st, 2016. Disease-spe-
cific follow-up (treatment and/or response) for more than
1 year was available for 413 patients. Disease-specific fol-
low-up was not available for five patients (1%) and for 39
patients (9%) the disease-specific follow-up was less than
1 year (26 died, 13 were lost to follow-up). 
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First-line treatment
Of the patients with detailed treatment information
available, 382 patients (97%) were treated with first-line
TKI therapy (imatinib n=295, 75%; nilotinib n=65, 17%;
dasatinib n=22, 6%) (Table 1), of whom 43% had received
hydroxyurea prior to or simultaneous with the start of
first-line TKI treatment. Hydroxyurea was the only report-
ed treatment in six patients (2%) and two elderly patients
with major comorbidities did not receive any treatment at
all (0.5%). One patient was pregnant at diagnosis and was
therefore treated first-line with interferon. One patient was
in chronic phase at diagnosis, but was initially treated with
leukapheresis and daunorubicin because of a hyperviscosi-
ty syndrome due to hyperleukocytosis at presentation
(leukocytes 525x109/L). This patient died 1 day after diag-
nosis. Leukapheresis was performed in two other patients
prior to imatinib treatment with white blood cell counts of
421x109/L and 606x109/L.
The majority of patients received the first-line TKI at stan-
dard doses: imatinib 400 mg QD (82%), nilotinib 300 mg
BID (89%) and dasatinib 100 mg QD (95%). First-line dose
adjustments were most frequently observed during imatinib
treatment, especially dose escalations and sequential dose
adjustments and/or interruptions (Figure 1). 
Response
Cytogenetic response data were available for 246 out of
434 chronic-phase-CML patients (57%) and molecular
response data for 326 out of 434 chronic-phase-CML
patients (75%). Patients with no cytogenetic and/or no
molecular response data available were significantly
older, had a higher comorbidity index, were less frequent-
ly included in first-line clinical trials and more frequently
treated in non-academic hospitals. The median time to
first complete cytogenetic response was 10 months. The
cumulative incidence of complete cytogenetic response
was 55% (95% CI: 49-62%) at 12 months and 73% (95%
CI: 67-79%) at 18 months (Figure 2). The median time to
first MMR was 13 months. The cumulative incidence of
MMR was 47% (95% CI: 42-52%) at 12 months and 63%
(95% CI: 57-68%) at 18 months (Figure 2). Deeper molec-
ular responses were achieved after a median treatment
duration of 30.5 months (MR4.0) and 43 months (MR4.5)
with cumulative incidence rates of 41% (95% CI: 35-
46%) and 69% (95% CI: 63-74%) for MR4.0 after 24
months and 48 months, respectively, and cumulative inci-
dence rates of 30% (95% CI: 25-35%) and 56% (95% CI:
50-62%) for MR4.5 after 24 months and 48 months,
respectively (Figure 2).   
Both cytogenetic and molecular response milestones
were achieved faster in patients treated upfront with a
second-generation TKI (Figure 3, Online Supplementary
Figures S1-S3). On initial treatment cumulative incidence
rates of the achievement of all response milestones were
significantly lower in patients treated with first-line ima-
tinib (Figure 3A, Online Supplementary Figures S1A, S2A and
S3A), but eventually, after switching TKI treatment, the
same response rates were achieved (Figure 3B, Online
Supplementary Figures S1B, S2B and S3B). 
Switching/discontinuation of tyrosine kinase inhibitor
treatment and time to effective treatment
Within the first 3 years after diagnosis, 44% (95% CI:
38-50%) of the 382 patients on first-line TKI treatment
discontinued their first-line treatment; 21% (95% CI: 17-
26%) due to TKI intolerance, 19% (95% CI: 15-24%) due
to treatment failure and 3% (95% CI: 1-5%) for other or
unknown reasons (Figure 4A). The most frequently
observed other reasons for first-line TKI discontinuation
were trial inclusion within 4 months after starting treat-
ment (n=5), inclusion in a TKI discontinuation trial (n=3)
and pregnancy (n=3). 
The 3-year cumulative incidence of TKI discontinuation
was not different between patients treated first-line with
imatinib or second-generation TKI (46% versus 38%,
P=0.104) (Figure 4B). TKI discontinuation due to TKI failure
was significantly more common in patients treated with
first-line imatinib (21% versus 13%, P=0.046) (Figure 4C).
TKI discontinuation due to TKI intolerance did not differ
according to whether the first-line treatment was with ima-
tinib or a second-generation TKI (21% versus 24%, P=0.854)
(Figure 4D). In total, up to five subsequent treatment
switches were observed (Online Supplementary Figure S4).
An overview of the reported types of intolerance on all
treatment lines and the actions that followed as a result of
the intolerance can be found in the Online Supplementary
Results section and Online Supplementary Table S2. 
The median time to sustained effective and tolerable
first-line treatment was 33 months and the cumulative
incidence was 56% (95% CI: 49-64%) after 4 years of
treatment: 51% (95% CI: 43-59%) with first-line imatinib
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Table 1. Patients’ characteristics at diagnosis for the sub-analysis of
patients with chronic-phase-CML treated with a TKI.
First line treatment                    Imatinib, n=295          2GTKI, n=87*
Male gender, n (%)                                168 (57)                          51 (59)
Age, years median (IQR)                    58 (42-69)                     57 (45-68)
Year of diagnosis, n (%)                                                                        
2008                                                           87 (30)                             3 (3)
2009                                                           77 (26)                             0 (0)
2010                                                           66 (22)                           14 (16)
2011                                                           40(14)                            32 (37)
2012 – April 2013                                     25 (9)                            38 (44)
Age-adjusted Charlson Comorbidity index, n (%)
0                                                                 98 (33)                           27 (31)
1-2                                                              87 (30)                           33 (38)
3-4                                                              65 (22)                           18 (21)
≥5                                                              45 (15)                            9 (10)
Sokal risk group, n (%)                                                                          
Low                                                           66 (26)                           14 (18)
Intermediate                                         112 (44)                          36 (47)
High                                                           77 (30)                           26 (34)
Unknown                                                      40                                    11
ELTS risk group, n (%)                                                                          
Low                                                          124 (49)                          33 (43)
Intermediate                                          88 (35)                           30 (40)
High                                                           43 (17)                           13 (17)
Unknown                                                      40                                    11
Treating hospital, n (%)                                                                        
Non-academic                                       226 (77)                          54 (62)
Academic                                                 69 (23)                         33 (38) #
Unknown                                                       0                                      0
Inclusion in 1st line clinical trial, n (%)                                              
No                                                             247 (86)                          66 (76)
Yes                                                            40 (14)                         21 (24) # 
Unknown                                                       8                                      0
*Nilotinib, n=65; dasatinib, n=22; #P<0.05 compared to imatinib-group. 2GTKI: second-
generation tyrosine kinase inhibitor; ELTS: EUTOS long-term survival.
treatment and 77% (95% CI: 57-97%) with first-line, sec-
ond-generation TKI treatment (P<0.001).
Progression during tyrosine kinase inhibitor therapy
The median observation period for progression of TKI-
treated chronic-phase-CML patients was 27 months
(range, 0-82 months). A total of 17 patients progressed
within 3 years, for a cumulative incidence of 3% after 1
year and 6% after 3 years. Progression occurred in 16
patients treated with first-line imatinib whereas it was
observed in only one patient treated upfront with a sec-
ond-generation TKI; the cumulative incidence rates for
progression after 3 years were 7% versus 1% (P=0.193) in
patients treated with frontline imatinib and frontline sec-
ond-generation TKI, respectively. 
Survival
The median observation time for survival of patients in
chronic phase at diagnosis was 5 years and 7 months
(range, 34-97 months). Eighty-two patients died during
follow-up (19%). Overall survival rates after 1, 2 and 4
years were 96% (95% CI: 94-98%), 92% (95% CI: 90-
95%) and 85% (95% CI: 81-88%), respectively. No signif-
icant differences in overall survival were observed when
overall survival was stratified by type of first-line TKI
treatment (P=0.244). The cumulative incidence of death
Real-world treatment outcome in CML
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Figure 1. Dose adjustments of first-
line tyrosine kinase inhibitors.
*P<0.05.
Figure 2. Achievement of cyto-
genetic and molecular
response milestones.
Cumulative incidence of first
and unconfirmed achievement
of CCyR, MMR, MR4.0 and
MR4.5. CCyR: complete cytoge-
netic response; MMR: major
molecular response; MR4.0:
0.01% on international scale;
MR4.5: 0.0032% on interna-
tional scale.
due to CML was 1% after 1 year, 2% after 2 years and 3%
after 4 years. Again, death due to CML was not signifi-
cantly different between patients treated first-line with
imatinib or a second-generation TKI (P=0.208).
Tyrosine kinase inhibitor stop eligibiity
Eligibility for a TKI stop attempt according to the
EURO-SKI criteria was evaluated for all 382 patients who
started first line TKI treatment. A total of 43 patients
I.G.P. Geelen et al.
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Figure 4. Discontinuation of first-line tyrosine kinase inhibitors. (A) Cumulative incidence of all causes of TKI discontinuation. (B) Cumulative incidence of TKI dis-
continuation, a comparison of imatinib with 2GTKI. (C) Cumulative incidence of TKI discontinuation due to TKI failure. (D) Cumulative incidence of TKI discontinuation
due to TKI intolerance. 2GTKI: second-generation tyrosine kinase inhibitor.
A B
A B
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Figure 3. Achievement of major molecular response on frontline imatinib and second-generation tyrosine kinase inhibitors. (A) Cumulative incidence of MMR on
initial treatment. (B) Cumulative incidence of overall MMR achievement (including patients who switched TKI). MMR: major molecular response; 2GTKI: second-gen-
eration tyrosine kinase inhibitors. 
(11%) met the eligibility criteria. During follow up 131
patients (34%) experienced a competing risk making them
ineligible for a (EURO-SKI) stop attempt: first-line TKI
failure (43%), less than 3 years on first- and second-line
TKI (29%), death (20%) and progression (8%). Censoring
occurred for 208 patients (55%): lost to disease-specific
follow-up within 3 years (80%), not (yet) achieved 3x
MR4.0 in 1 year (19%), emigration (1%) and unknown rea-
son for TKI switch (0.5%). The cumulative incidences of
stop attempt eligibility after 4 and 6 years were 24% (95%
CI, 17-30%) and 31% (95% CI, 23-38), respectively
(Figure 5A). The cumulative incidence of TKI stop eligibil-
ity after first line 2GTKI treatment was numerically higher
than after imatinib treatment, but this did not reach statis-
tical significance (P=0.147) (Figure 5B).
Treatment and outcome of patients presenting 
in advanced-phase-chronic myeloid leukemia
The 15 patients who presented in advanced disease
phase at diagnosis (8 accelerated phase and 7 blast crisis)
were mainly treated upfront with a TKI (6 accelerated
phase and 4 blast crisis). One patient in blast crisis was
started on chemotherapy + TKI treatment and treatment
was unknown for two other patients in blast crisis.
Allogeneic stem cell transplantation was performed in
three patients with accelerated-phase-CML and three
with blast crisis. The median survival after diagnosis was
1.4 years in patients with accelerated-phase-CML and not
reached in the blast crisis patients. The 5-year overall sur-
vival rates were 38% and 57%, respectively.
Discussion
Our nationwide, population-based study confirms the
excellent results of TKI treatment in CML patients observed
in randomized controlled trials outside clinical trials and
adds insights into the patterns of TKI switching and
patients’ outcome. Moreover, this study presents the first
real-world data on the proportion of patients becoming eli-
gible for an attempt to achieve treatment-free remission. 
The baseline characteristics of the Dutch CML popula-
tion are comparable to those of patients in other popula-
tion-based CML registries.6,16,17 In contrast, patients includ-
ed in the ENESTnd and DASISION randomized controlled
trials18,19 were 10 years younger than those in our real-
world cohort. Since nilotinib and dasatinib were both reg-
istered for first-line treatment in December 2010, the
majority of patients treated with second-generation TKI
were diagnosed in the second half of the inclusion period
and therefore experienced a shorter follow-up period.
Because of the relatively low number of individual
patients treated upfront with nilotinib and dasatinib, it
was decided to combine these two groups of patients for
comparisons with the imatinib-treated patients. 
Our real-world observations show that TKI therapy is
effective and tolerable in the majority of patients, but fre-
quent dose adjustments and temporary treatment inter-
ruptions are required (45% of patients treated upfront
with imatinib and 31-32% of patients treated with a sec-
ond-generation TKI). Only half (54%) of all imatinib-treat-
ed patients with chronic-phase-CML were estimated to
remain on first-line TKI 3 years after treatment initiation
in our observational cohort. This rate of TKI treatment
persistence is notably lower than the rates observed in the
ENESTnd and DASISION randomized controlled trials in
which 62% and 69% of patients were still on their first-
line imatinib treatment after 3 years.20,21 For nilotinib and
dasatinib these rates were 71-74% and 71%, respective-
ly,20,21 while we observed a 3-year treatment persistence
rate of only 62% in patients treated with second-genera-
tion TKI. These differences were mainly due to the higher
TKI discontinuation rates due to TKI intolerance observed
in our real-world setting. It can be hypothesized that the
threshold for TKI switching due to intolerance for both
physicians and patients is lower in subjects treated outside
a clinical trial. In concordance with our study, Castagnetti
et al. reported a treatment persistence rate of 59% in
patients treated with imatinib after a median of 48 months
follow-up in a real-world setting in Italy, also because of
frequent TKI switches due to intolerance.22 
The observations of earlier and higher rates of achieve-
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Figure 5. Eligibility to attempt cessation of tyrosine kinase inhibitor therapy according to EURO-SKI criteria. (A) Cumulative incidence of overall eligibility of patients
with chronic-phase-CML treated first-line with a TKI. (B) Comparison of cumulative incidences in patients treated upfront with imatinib or 2GTKI. 2GTKI: second-gen-
eration tyrosine kinase inhibitor. 
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ment of the important response milestones, complete
cytogenetic response and MMR, in patients treated with
first-line, second-generation TKI in our real-world cohort
confirm the reproducibility of the superior efficacy results
of first-line, second-generation TKI found in the two large
randomized controlled trials.4,5 Of note, the 3-year MMR
rate achieved in our real-world cohort with first-line, sec-
ond-generation TKI (84%) is even higher than the rates
recorded in the randomized controlled trials (69-73%).
Differences in methodology and study design of our
observational study and the randomized controlled trials
may have contributed to the variation in findings. A limi-
tation to population-based cohort studies is that patients
are not monitored as strictly as during the closely super-
vised clinical follow-up in trials. Furthermore, in our reg-
istry, patients with more favorable baseline characteristics
more often had cytogenetic and molecular response analy-
ses performed. This may in part explain the relatively high
remission rates we observed.  
Real-world data not only give insight into responses on
first-line treatments, but also provide information on the
overall response on subsequent treatment lines, in contrast
to data from the currently published clinical trials. For
example, the data from our nationwide registry demon-
strate that 91% of all chronic-phase-CML patients treated
with a TKI eventually achieved complete cytogenetic
response and 88% reached a MMR after 4 years, whereas
the results from randomized controlled trials on core treat-
ment were significantly lower at this time point. The
observational data on overall response do, therefore,
reflect relevant patients’ outcomes much better than the
clinical trial results do. Our overall response rates are com-
parable to those observed in other population-based reg-
istries.16,22,23 The observation that patients treated upfront
with imatinib or a second-generation TKI eventually
achieved comparable complete cytogenetic response and
MMR rates, whether or not preceded by one or more
treatment switches, has also been recognized before.23 An
analysis of long-term molecular response on first-line
treatment even showed that patients treated with ima-
tinib 400 mg QD only can reach MMR rates nearly similar
to those treated with imatinib 800 mg QD, nilotinib and
dasatinib after 5 years.24
To our knowledge, this is the first observational study
comparing deep molecular responses achieved on ima-
tinib with deep molecular responses achieved on second-
generation TKI. Of note, comparative analyses were ham-
pered in our study by a relatively low number of patients
receiving second-generation TKI and their shorter follow-
up period. Despite this, we were still able to show that
MR4.0 and MR4.5 were achieved significantly faster in the
real-world when treatment was initiated with a second-
generation TKI than when the initial treatment was ima-
tinib, independently of subsequent treatment lines. In the
randomized controlled trials both higher24 and lower4,5
cumulative response rates were observed than in our real-
life cohort. These deep responses are especially interesting
in the light of eligibility for an attempt to stop TKI thera-
py. Together with the duration of TKI treatment and
switching history, a durable deep molecular remission is
the main selection criterion currently used in trials investi-
gating treatment-free remission. In a previous analysis of
patients in first-line clinical trials, after 8 years of imatinib
treatment, the cumulative incidence of stable (≥ 24
months) MR4.5, determined on an intent-to-treat basis, was
36.5%, suggesting that this proportion may be eligible for
treatment-free remission.25 In our population-based study,
the eligibility criteria of the largest treatment-free remis-
sion trial to date, EURO-SKI, were used to evaluate this
endpoint and showed a cumulative incidence of 31% after
6 years. Although we observed a higher eligibility rate in
patients treated upfront with a second-generation TKI
than in those treated with imatinib, the difference did not
reach statistical significance possibly because of the rela-
tively low number of patients who had started on a sec-
ond-generation TKI and had a follow-up beyond 3 years. 
In conclusion, this population-based analysis showed
overall favorable treatment responses compared to those
in randomized controlled trials, which could be attributed
to dose adjustments and subsequent treatment lines in the
real-world setting. It also showed that the long-term out-
come of patients initially treated with imatinib is excellent
when these patients are switched to second-generation
TKI when needed. The cumulative incidence of patients
eligible to attempt to stop their TKI to achieve treatment-
free remission was 31% after 6 years when the EURO-SKI
criteria were applied. 
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